Colorectal Cancer Heterogeneity and the Impact on Precision Medicine and Therapy EfficacyGerardo Rosati, Antonio Avallone, Giuseppe Aprile et al.|Biomedicines|2022Cited by 14
Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experienceMariangela Ciccarese, Giammarco Surico, Vito Lorusso et al.|Breast Cancer Research and Treatment|2017Cited by 12
Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer patients: safety and efficacy. An Italian experienceE.S. Lutrino, Saverio Cinieri, Laura Orlando et al.|Tumori Journal|2019Cited by 6
BRCA1 and 2 Mutations and Efficacy of Pembrolizumab-Based Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Real-World Multicenter AnalysisPalma Fedele, Gennaro Gadaleta‐Caldarola, Alessandro Rizzo et al.|Journal of Clinical Medicine|2025Cited by 4
Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer (ABC) patients: Results on safety and efficacy—An Italian multicenter experience.Stefania Eufemia Lutrino, Saverio Cinieri, Laura Orlando et al.|Journal of Clinical Oncology|2016Cited by 3